Page last updated: 2024-08-05 11:13:12

thiazolidinone

null

ChEBI ID: 48891

Members (11)

MemberDefinitionRole
10058-F4A member of the class of thiazolidinones that is 2-sulfanylidene-1,3-thiazolidin-4-one which is substituted at position 5 by a (4-ethylphenyl)methylidene group. It is a cell permeable inhibitor of c-Myc-Max dimerization and exhibits antitumour effects in vivo. It downregulates c-Myc expression and upregulates CDK inhibitors, p21 and p27 resulting in the inhibition of proliferation, induction of apoptosis and cell cycle arrest in G0/G1 phase.10058-F4
cgp 52608CGP 52608
ciglitazoneAn aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.ciglitazone
DPI2A thiazolidinone that is 2-sulfanylidene-1,3-thiazolidin-4-one substituted by 3-{[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl and 4-ethylbenzylidene groups at positions 3 and 5, respectively. It is a ferroptosis inducer.DPI2
GSK1059615A thiazolidinone that is the 5-{[4-(pyridin-4-yl)quinolin-6-yl]methylene} derivative of 1,3-thiazolidine-2,4-dione. A PI3K inhibitorGSK1059615
latrunculin aA bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.latrunculin A
latrunculin bA macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica.latrunculin B
rhodaninerhodanine
risarestatrisarestat
troglitazonetroglitazone
troglitazone sulfate[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] hydrogen sulfate

Research

Studies (3,776)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-1990120 (3.18)18.7374
1990's577 (15.28)18.2507
2000's2,008 (53.18)29.6817
2010's934 (24.74)24.3611
2020's137 (3.63)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials172 (4.22%)5.53%
Reviews243 (5.97%)6.00%
Case Studies53 (1.30%)4.05%
Observational0 (0.00%)0.25%
Other3,604 (88.51%)84.16%